Oligoprogression in Metastatic, Castrate-Resistant Prostate Cancer—Prevalence and Current Clinical Practice

Oligoprogression in Metastatic, Castrate-Resistant Prostate Cancer—Prevalence and Current Clinical Practice

AimsOligoprogression is poorly defined in current literature. Little is known about the natural history and significance of oligoprogression in patients with hormone-resistant prostate cancer on abiraterone or enzalutamide treatment [termed androgen receptor-targeted therapy (ARTT)]. The aim of this...

Full description

Bibliographic Details
Main Authors:	Priyanka H. Patel, Nina Tunariu, Daniel S. Levine, Johann S. de Bono, Rosalind A. Eeles, Vincent Khoo, Julia Murray, Christopher C. Parker, Angela Pathmanathan, Alison Reid, Nicholas van As, Alison C. Tree
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-05-01
Series:	Frontiers in Oncology
Subjects:	oligoprogression stereotactic body radiotherapy castrate resistant prostate cancer abiraterone enzalutamide Androgen receptor targeted therapy
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2022.862995/full

Similar Items

Survival outcomes and prognostic factors for first-line abiraterone acetate or enzalutamide in patients with metastatic castration-resistant prostate cancer
by: Chi-Shin Tseng, et al.
Published: (2023-06-01)

Efficacy and safety of bipolar androgen therapy in castration-resistant prostate cancer following abiraterone or enzalutamide resistance: A systematic review
by: Xiangyun You, et al.
Published: (2023-04-01)

Prognostic impact of dose reduction in androgen receptor pathway inhibitors for castration-resistant prostate cancer
by: Shigetomo Yamada, et al.
Published: (2022-03-01)

Real-world Treatment Sequencing in Patients with Metastatic Castration-resistant Prostate Cancer: Results from the Prospective, International, Observational Prostate Cancer Registry
by: Anders Bjartell, et al.
Published: (2022-11-01)

Improving quality of life in metastatic castration-resistant prostate cancer: the role of androgen receptor axis-targeted agents
by: Monika Kuzma, et al.
Published: (2023-07-01)

Cost-effectiveness and budget impact analysis of enzalutamide in comparison to abiraterone in treatment of metastatic prostate cancer resistant to castration in Iran
by: Zahra Goudarzi, et al.
Published: (2024-02-01)

Assessment of androgen receptor signaling inhibitors therapy in metastatic hormone-sensitive prostate cancer
by: Jukapun Yoodee, et al.
Published: (2022-11-01)

Real‑world survival outcome comparing abiraterone acetate plus prednisone and enzalutamide for nonmetastatic castration‐resistant prostate cancer
by: Takuya Tsujino, et al.
Published: (2023-10-01)

Enzalutamide versus Abiraterone Acetate as first-line treatment of castration resistant metastatic prostate cancer in geriatric (≥75) patients
by: Ali Alkan, et al.
Published: (2021-09-01)

Enzalutamide versus abiraterone as a first-line endocrine therapy for castration-resistant prostate cancer (ENABLE study for PCa): a study protocol for a multicenter randomized phase III trial
by: Kouji Izumi, et al.
Published: (2017-10-01)

Enzalutamide Versus Abiraterone plus Prednisolone Before Chemotherapy for Castration-resistant Prostate Cancer: A Multicenter Randomized Controlled Trial
by: Kouji Izumi, et al.
Published: (2022-07-01)

Androgen receptor targeted therapies in metastatic castration-resistant prostate cancer – The urologists' perspective
by: Jo-Lynn Tan, et al.
Published: (2017-12-01)

Investigation into the Optimal Strategy of Radium-223 Therapy for Metastatic Castration-Resistant Prostate Cancer
by: Yasuo Oguma, et al.
Published: (2022-09-01)

Outcomes Management in a Real-World Evidence Context: The Case of Abiraterone and Enzalutamide in the Treatment of Metastatic Castration-Resistant Prostate Cancer
by: Pedro Cardoso, et al.
Published: (2020-05-01)

Nonregional Lymph Node Metastasis as a Predictor of Early Progression When Using Androgen Receptor Targeting Agents in Patients With Metastatic Castration-Resistant Prostate Cancer Without Previous Chemotherapy
by: Sihyeon Kim, et al.
Published: (2023-11-01)

THE PLACE OF ENZALUTAMIDE IN THE SERIAL TREATMENT OF TREATMENT-RESISTANT PROSTATE CANCER
by: A. A. GRITSKEVICH, et al.
Published: (2017-06-01)

A Novel, Circulating Tumor Cell Enrichment Method Reduces ARv7 False Positivity in Patients with Castration-Resistant Prostate Cancer
by: Takehiko Nakasato, et al.
Published: (2020-03-01)

The evolution of prostate cancer therapy: targeting the androgen receptor (AR)
by: Jeanny B. Aragon-Ching
Published: (2014-10-01)

Androgen Receptor and Its Splicing Variant 7 Expression in Peripheral Blood Mononuclear Cells and in Circulating Tumor Cells in Metastatic Castration-Resistant Prostate Cancer
by: Mercedes Marín-Aguilera, et al.
Published: (2020-01-01)

Clinical impact of volume of disease and time of metastatic disease presentation on patients receiving enzalutamide or abiraterone acetate plus prednisone as first-line therapy for metastatic castration-resistant prostate cancer
by: Pier Vitale Nuzzo, et al.
Published: (2023-02-01)

Prostate-specific antigen doubling time predicts the efficacy of site-directed therapy for oligoprogressive castration-resistant prostate cancer
by: Taketo Kawai, et al.
Published: (2023-12-01)

Metastasis-Directed Stereotactic Body Radiotherapy in Prostate Cancer Patients Treated with Systemic Therapy and Undergoing Oligoprogression: Report on 11 Consecutive Cases
by: Emanuele Chioccola, et al.
Published: (2024-04-01)

Indirect comparison between abiraterone acetate and enzalutamide for the treatment of metastatic castration-resistant prostate cancer: a systematic review
by: Wei Zhang, et al.
Published: (2017-01-01)

Utilization Trends of Novel Hormonal Agents in Metastatic Castration-Resistant Prostate Cancer in Quebec
by: Jason Hu, et al.
Published: (2022-11-01)

Real‐world first‐line systemic therapy patterns in metastatic castration‐resistant prostate cancer
by: Angelyn Anton, et al.
Published: (2022-05-01)

Stereotactic Radiation for Oligometastatic and Oligoprogressive Stage IV Breast Cancer: A Case-Based Review
by: Gary M. Freedman, et al.
Published: (2023-02-01)

Concomitant antihypertensive medication and outcome of patients with metastatic castration‐resistant prostate cancer receiving enzalutamide or abiraterone acetate
by: Ondřej Fiala, et al.
Published: (2024-01-01)

Development and validation of a survival nomogram and calculator for male patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate and/or enzalutamide
by: Takashi Kawahara, et al.
Published: (2023-03-01)

Early abiraterone acetate treatment is beneficial in Japanese castration-resistant prostate cancer after failure of primary combined androgen blockade
by: Takashi Nagai, et al.
Published: (2018-03-01)

Optimisation of second line antihormonal treatment for castration resistant metastatic prostate cancer
by: Kullmann Tamás, et al.
Published: (2022-04-01)

Meta-analysis to evaluate the comparative effectiveness of enzalutamide and abiraterone acetate for first-line treatment of metastatic castration-resistant prostate cancer in real-world settings
by: Armen Aprikian, et al.
Published: (2025-02-01)

Osteoblast Secretome Modulated by Abiraterone Treatment Affects Castration Resistant Prostate Cancer Cell Proliferation
by: Michele Iuliani, et al.
Published: (2022-09-01)

Modern antiandrogenic therapy of patients with castration-resistant prostate cancer without metastases
by: S. V. Popov
Published: (2020-12-01)

Selective androgen receptor degrader (SARD) to overcome antiandrogen resistance in castration-resistant prostate cancer
by: Meng Wu, et al.
Published: (2023-01-01)

Effectiveness of radiotherapy in delaying treatment changes in primary or secondary immunorefractory oligoprogressive patients: preliminary results from a single-center study
by: Valentina Zagardo, et al.
Published: (2024-10-01)

Effectiveness of Stereotactic Ablative Radiotherapy for Systemic Therapy Respondents with Inoperable Pulmonary Oligometastases and Oligoprogression
by: Chin-Beng Ho, et al.
Published: (2023-04-01)

Role of Consolidative Stereotactic Body Radiation Therapy in Oligoresistant/Oligoprogressive Pulmonary Parenchymal Metastases
by: Berber T, et al.
Published: (2022-08-01)

The association of AR-V7 with resistance to Abiraterone in metastatic castration-resistant prostate cancer
by: Shuo Wang, et al.
Published: (2022-03-01)

Safety and efficacy of abiraterone acetate in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: an Italian multicenter “real life” study
by: Luca Cindolo, et al.
Published: (2017-11-01)

Mental health care utilization among men with castration‐resistant prostate cancer receiving abiraterone or enzalutamide
by: Phoebe A. Tsao, et al.
Published: (2023-08-01)